Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw its stock price plummet by 6.09% during the Friday trading session, following the company's mixed fourth-quarter earnings report and disappointing guidance for the upcoming year.

The generic drugmaker reported adjusted earnings per share (EPS) of $0.12 for the fourth quarter of 2024, missing analysts' consensus estimate of $0.15. Despite beating revenue expectations with $730.52 million, up 18% year-over-year, the company's bottom line was impacted by higher spending on research and development, as well as commercial initiatives aimed at driving future growth.

Furthermore, Amneal's guidance for the full year 2025 fell short of analysts' expectations. The company projected revenues of $3 billion to $3.1 billion and adjusted EPS of $0.65 to $0.70, compared to the consensus estimates of $2.9 billion and $0.71, respectively. This disappointing outlook, coupled with the Q4 earnings miss, weighed heavily on investor sentiment, leading to the significant stock price decline.